Article in the Financial Times highlights Birmingham's medical excellence
Finally Birmingham is starting to gain national media recognition for its medical excellence after an article by Andrew Ward was published this week in the Financial Times.
Cure Leukaemia Co-Founder Professor Charlie Craddock features in the piece which highlights the key elements that set Birmingham apart:
“To be competitive in clinical research, you need a large ethnically diverse population, you need clinical excellence and you need infrastructure,” says Charles Craddock, director of the centre for clinical haematology at the Queen Elizabeth Hospital.
“Birmingham has all three.”
As a result of this, pioneering drug treatments are available to blood cancer patients who have exhausted all options through the NHS in this region. However, specialist research nurses are essential to bridge the gap between patients and these therapies.
Without Cure Leukaemia, blood cancer patients in Birmingham and the Midlands would not have access to these potentially life-saving drug treatments because there would be no specialist research nurses to administer them.
This is why articles such as this are so important to communicate Birmingham's medical excellence and why more funds raised for Cure Leukaemia really can save lives.
The article is also timely during Blood Cancer Awareness Month as Cure Leukaemia's 'Just One More' campaign enters the final 12 hours. We are trying to raise £40,000 in September, enough to fund a specialist research nurse for a year. There is still time to donate 'Just One More' £ to help us reach this goal:
Text: VITC15 £1 to 70070
We are close to the target and your £1 could really make a difference.
The article finishes with this powerful quote from Professor Craddock:
“There are already 100s of people who are alive today who wouldn’t have been but for taking part in our trials.”
Help us save 100s more.
To read the full article click HERE (subscription required)